Premium
Weight changes with depot neuroleptic maintenance therapy
Author(s) -
Johnson D. A. W.,
Breen M.
Publication year - 1979
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1979.tb00252.x
Subject(s) - maintenance therapy , fluphenazine , depot , weight gain , schizophrenia (object oriented programming) , psychiatry , medicine , psychosis , psychology , body weight , chemotherapy , haloperidol , archaeology , dopamine , history
A prospective study of schizophrenic patients prescribed injectable depot neuroleptic drugs as maintenance therapy showed a clinically significant weight gain in 55 % of patients. No significant difference was shown between flupenthixol decanoate and fluphenazine decanoate, nor was a clinically meaningful relationship shown with dose, or the use of anti‐parkinsonian drugs. The weight gain continued for at least 2 years following a mental state relapse. It is suggested that the monitoring of weight and giving of appropriate advice on diet are two essentials in maintenance therapy of chronic schizophrenia.